£4.0M
The seed round was backed by Redalpine, IQ Capital Partners, and Seedcamp.
DaltonTx
DaltonTx develops adaptive AI platforms to accelerate drug discovery for pharmaceutical and biotech organisations.
£4.0MTotal raised
DaltonTx builds adaptive, AI-enabled discovery platforms designed to integrate into pharmaceutical, biotechnology, and contract research workflows. The company aims to improve the economics and timelines of research and development for both small molecules and biologics.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from DaltonTx's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
GP
Garry Pairaudeau
Co-Founder
Garry brings pharmaceutical and biotech operating experience from leadership roles at Exscientia and AstraZeneca. He is currently the chief executive and cofounder of DaltonTx.
LinkedInAR
Adrian Rossall
Co-Founder
Adrian brings platform engineering and drug design experience from roles at AstraZeneca, Exscientia, and Science Architechs. He now serves as cofounder and chief technology officer at DaltonTx.
LinkedInAB
Anthony Bradley
Co-Founder
Anthony brings research and design development experience in chemistry, artificial intelligence, and computation from roles at Exscientia and the University of Liverpool. He now serves as co-founder and chief scientific officer at DaltonTx.
LinkedInCD
Charlotte Deane
Co-Founder